Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FUCA1 | P04066 | 5/20 | 1.00 |
| ▸ | FUCA2 | Q9BTY2 | 1/20 | 1.00 |
| ▸ | GLB1 | P16278 | 1/20 | 0.58 |
| ▸ | GBA1 | P04062 | 5/20 | 0.54 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | GANAB | Q14697 | 1/20 | 0.46 |
| ▸ | MAN2B1 | O00754 | 1/20 | 0.46 |
| ▸ | MAN2B2 | Q9Y2E5 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Deoxyfuconojirimycin SCHEMBL15686574 | 1.00 | FUCA1 (1.00) | FUCA1FUCA2GLB1GBA1GLA | |
| Deoxyfuconojirimycin SCHEMBL13876082 | 1.00 | FUCA1 (1.00) | FUCA1FUCA2GLB1GBA1GLA | |
| Deoxyfuconojirimycin SCHEMBL4378188 | 1.00 | FUCA1 (1.00) | FUCA1FUCA2GLB1GBA1GLA | |
| Deoxyfuconojirimycin SCHEMBL1867289 | 1.00 | FUCA1 (1.00) | FUCA1FUCA2GLB1GBA1GLA | |
| Deoxyfuconojirimycin SCHEMBL12581516 | 1.00 | FUCA1 (1.00) | FUCA1FUCA2GLB1GBA1GLA | |
| Deoxyfuconojirimycin SCHEMBL9999893 | 1.00 | FUCA1 (1.00) | FUCA1FUCA2GLB1GBA1GLA | |
| Deoxyfuconojirimycin SCHEMBL13328524 | 1.00 | FUCA1 (1.00) | FUCA1FUCA2GLB1GBA1GLA | |
| Deoxyfuconojirimycin SCHEMBL2436650 | 1.00 | FUCA1 (1.00) | FUCA1FUCA2GLB1GBA1GLA | |
| Deoxyfuconojirimycin SCHEMBL15691930 | 1.00 | FUCA1 (1.00) | FUCA1FUCA2GLB1GBA1GLA | |
| Deoxyfuconojirimycin SCHEMBL13876087 | 1.00 | FUCA1 (1.00) | FUCA1FUCA2GLB1GBA1GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10842784-B2 | Treatment of energy utilization disease | VIDA PHARMA LIMITED (GB) | 2020-11-24 | — | — | US | disclosed |
| US-20110237538-A1 | TREATMENT OF LYSOSOMAL STORAGE DISORDERS AND OTHER PROTEOSTATIC DISEASES | SUMMIT CORPORATION PLC (GB) | 2011-09-29 | — | — | US | disclosed |
| US-20110015226-A1 | Treatment of Energy Utilization Disease | SUMMIT CORPORATION PLC (GB) | 2011-01-20 | — | — | US | disclosed |
| US-20090117083-A1 | IMMUNOMODULATORY ALKALOIDS | M N L PHARMA LIMITED (UK) | 2009-05-07 | — | — | US | disclosed |
| US-20090047306-A1 | ADJUVANT COMPOSITIONS | M N L PHARMA LIMITED (UK) | 2009-02-19 | — | — | US | disclosed |
| US-6831176-B2 | Reacting a ketoaldonic acid methyl ester of the sugar with the protected hydroxyl groups with a an alkylamine or hydroxyalamine salt in an organic solvent with a tert-amine to react with acid generated to produce oxime methyl ester | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY | 2004-12-14 | — | — | US | disclosed |
| US-6740780-B2 | L-XYLO-5-HEXULOSONIC ACID HYDRAZIDE OXIME | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY | 2004-05-25 | — | — | US | disclosed |
| US-6683185-B2 | FROM HYDROXYL-PROTECTED OXIME INTERMEDIATES, INCLUDES FORMATION OF A LACTAM WHICH IS REDUCED TO THE HEXITOL; CHEMICAL INTERMEDIATES TO D-DIDEOXYGALACTO-NOJIRIMYCINS | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY | 2004-01-27 | — | — | US | disclosed |
| US-6653480-B2 | Generating aldonic-5-oxime ethyl ester with protected hydroxyls; obtain keto-methyl sugar ester, incubate with hydroxylamine hydrochloride, separate oxime methyl ester from mixture | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY | 2003-11-25 | — | — | US | disclosed |
| US-6653482-B2 | The ketoaldonic acid methyl ester is converted into the oxime which is then reduced to the amine which cyclizes to give the lactam which is then reduced to the imino sugar by borane or a metal hydride | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY | 2003-11-25 | — | — | US | disclosed |
| EP-0576592-B1 | OLIGOSACCHARIDE ENZYME SUBSTRATES AND INHIBITORS: METHODS AND COMPOSITIONS | SCRIPPS RESEARCH INST (US) | 2000-05-31 | — | — | EP | disclosed |
| US-5759823-A | MIXING IN AQUEOUS MEDIUM ACTIVATED DONOR MONOSACCHARIDE WITH ACCEPTOR SACCHARIDE IN PRESENCE OF GLYCOSYLTRANSFERASE, MAINTAINING TO GLYCOSYLATE ACCEPTOR SACCHARIDE | SCRIPPS RESEARCH INSTITUTE (US) | 1998-06-02 | — | — | US | disclosed |
| US-5596005-A | GLYCOSIDASE INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 1997-01-21 | — | — | US | disclosed |
| US-5593887-A | Oligosaccharide enzyme substrates and inhibitors: methods and compositions | THE SCRIPPS RESEARCH INSTITUTE (US) | 1997-01-14 | — | — | US | disclosed |
| EP-0576592-A4 | OLIGOSACCHARIDE ENZYME SUBSTRATES AND INHIBITORS: METHODS AND COMPOSITIONS | SCRIPPS RESEARCH INST (US) | 1996-01-24 | — | — | EP | disclosed |
| US-5461143-A | Oligosaccharide enzyme substrates and inhibitors: methods and compositions | THE SCRIPPS RESEARCH INSTITUTE (US) | 1995-10-24 | — | — | US | disclosed |
| EP-0576592-A1 | OLIGOSACCHARIDE ENZYME SUBSTRATES AND INHIBITORS: METHODS AND COMPOSITIONS | THE SCRIPPS RESEARCH INSTITUTE (US) | 1994-01-05 | — | — | EP | disclosed |
| US-5276120-A | Reductively cyclizing an azido-substituted alpha-ketose phosphate; palladium catalyzed | THE SCRIPPS RESEARCH INSTITUTE (US) | 1994-01-04 | — | — | US | disclosed |
| WO-1992021657-A1 | OMEGA-DEOXY-AZASUGARS | THE SCRIPPS RESEARCH INSTITUTE (US) | 1992-12-10 | — | — | WO | disclosed |
| WO-1992016640-A1 | OLIGOSACCHARIDE ENZYME SUBSTRATES AND INHIBITORS: METHODS AND COMPOSITIONS | THE SCRIPPS RESEARCH INSTITUTE (US) | 1992-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237538-A1 | TREATMENT OF LYSOSOMAL STORAGE DISORDERS AND OTHER PROTEOSTATIC DISEASES | GAA, MAN2B1, GBA1 | FUCA1 17/4885FUCA2 18/4885GLB1 33/4885 |
| US-20090117083-A1 | IMMUNOMODULATORY ALKALOIDS | IL2, IL2RA, IDO2 | FUCA1 4102/4885FUCA2 1989/4885GLB1 4128/4885 |
| US-10842784-B2 | Treatment of energy utilization disease | IRS1, SLC2A1, INSR | FUCA1 1506/4885FUCA2 1138/4885GLB1 1210/4885 |
| US-20110015226-A1 | Treatment of Energy Utilization Disease | IRS1, SLC2A1, INSR | FUCA1 1506/4885FUCA2 1138/4885GLB1 1210/4885 |
| US-20090047306-A1 | ADJUVANT COMPOSITIONS | CD4, LY96, CD209 | FUCA1 107/4885FUCA2 83/4885GLB1 2487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.